Nefrocarnit (Levocarnitine)

Levocarnitine, the active ingredient in Nefrocarnit, is a carnitine supplement presented as an oral supplement for oral use. It is used to address primary or secondary carnitine deficiency and to support fatty‑acid metabolism in individuals requiring nutritional supplementation.

GNH USA supplies Nefrocarnit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Nefrocarnit (levocarnitine) is employed in conditions related to impaired carnitine metabolism or increased nutritional demand. - Carnitine deficiency: restores normal carnitine levels and improves energy production. - Inborn errors of metabolism: supports fatty‑acid oxidation in patients with metabolic disorders. - Nutritional supplementation: provides additional carnitine for patients with increased metabolic needs, such as those on dialysis or with malnutrition.

Levocarnitine is generally well tolerated, but some adverse reactions have been reported.

Common Side Effects: - Nausea: mild stomach upset. - Diarrhea: loose stools. - Muscle cramps: transient discomfort. - Fishy body odor: odor of urine or sweat.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, swelling. - Seizures: rare neurological events. - Cardiac arrhythmia: uncommon but reported in high doses.

When using Nefrocarnit, consider the following safety measures. - Assess deficiency: confirm carnitine deficiency before initiating therapy. - Renal function: adjust use in patients with severe renal impairment. - Pregnancy and lactation: use only if clearly needed; data are limited. - Concomitant medications: monitor for interactions with valproic acid or other agents affecting carnitine metabolism. - Allergic reactions: discontinue if signs of hypersensitivity appear. - Store below 25°C: keep in the original pack, protect from moisture.

Levocarnitine may interact with certain medicines; review the following categories.

Major Interactions (Avoid): - None identified: no major drug interactions have been documented for levocarnitine.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase carnitine depletion, monitor levels. - Anticonvulsants (e.g., phenobarbital, carbamazepine): can enhance carnitine metabolism, consider supplementation. - Dialysis: removes carnitine, dosing may need adjustment. - Thyroid hormones: may alter carnitine requirements, monitor clinical response.